Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% for Primary Immunodeficiency Diseases
NCT00811174Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Jan 2009
- Primary completion
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human normal immunoglobulin in primary immunodeficiency disease (PID), sponsored by Octapharma. Started Jan 2009; status: terminated.
02
Drugs
human normal immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT00811174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811174.